ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
Published Date: August 2025
|
Report Code: QYRE-Auto-14N9172
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Attention Deficit Hyperactivity Disorder ADHD Market Size Status and Forecast 2022
BUY CHAPTERS

Global Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Code: QYRE-Auto-14N9172
Report
August 2025
Pages:100
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
NEOS Therapeutics
Mallinckrodt plc
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengdafenhai
Highland Therapeutics
Jubilant Life Sciences
Medice Arzneimittel Putter
Lannett

Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Size

The global Attention Deficit Hyperactivity Disorder (ADHD) market size was US$ 13430 million in 2024 and is forecast to a readjusted size of US$ 18550 million by 2031 with a CAGR of 4.9% during the forecast period 2025-2031.

Attention Deficit Hyperactivity Disorder (ADHD) Sales Market

Attention Deficit Hyperactivity Disorder (ADHD) Sales Market

Effective treatment of ADHD. ADHD refers to a group of syndromes that occur in childhood and are characterized by obvious difficulty in concentration, short duration of attention, hyperactivity or impulsivity compared with children of the same age.
The ADHD market is expanding rapidly due to rising global awareness and increasing diagnosis rates, especially in children and young adults. Improved understanding of mental health conditions among healthcare providers, educators, and parents has contributed to earlier identification and more proactive treatment approaches. Government-supported initiatives, mental health screenings in schools, and expanded insurance coverage have made ADHD treatment more accessible in both developed and developing regions. Furthermore, advancements in pharmacological research have led to the availability of more effective, long-acting, and better-tolerated medications, expanding the range of treatment options. The rise of digital health platforms, including telemedicine and mobile apps for symptom monitoring, has also made ADHD management more convenient and efficient. Growing adult ADHD diagnosis, driven by increased public discussion and reduced stigma, is further contributing to market growth.
Despite the increasing demand, the ADHD market faces several significant challenges. One of the main concerns is the potential overdiagnosis or misdiagnosis of ADHD, particularly in children, leading to inappropriate or excessive use of medications. Differentiating ADHD from other behavioral or psychological disorders like anxiety, autism, or learning disabilities remains complex, often requiring multidisciplinary assessments. Medication side effects, such as insomnia, appetite suppression, and cardiovascular concerns, can lead to treatment non-compliance or discontinuation. There are also regulatory barriers around stimulant drug prescriptions due to their potential for abuse and dependency. Additionally, disparities in healthcare infrastructure and limited access to trained mental health professionals in low-income and rural areas hinder timely diagnosis and treatment. Cultural stigma around psychiatric disorders still discourages many individuals and families from seeking medical help, especially in emerging markets.
The global Attention Deficit Hyperactivity Disorder (ADHD) market is strategically segmented by company, region (country), by Type, and by Distribution Channel. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on revenue and forecasts across regions, by Type, and by Distribution Channel for 2020-2031.
Market Segmentation

Scope of Attention Deficit Hyperactivity Disorder (ADHD) Sales Market Report

Report Metric Details
Report Name Attention Deficit Hyperactivity Disorder (ADHD) Sales Market
Forecasted market size in 2031 US$ 18550 million
CAGR 4.9%
Forecasted years 2025 - 2031
By Type: (Dominant Segment vs High-Margin Innovation)
  • Stimulant
  • Non-stimulant
By Application: (Core Demand Driver vs Emerging Opportunity)
  • Hospital Pharmacy
  • Retail Pharmacy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company: Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, Zhengdafenhai, Highland Therapeutics, Jubilant Life Sciences, Medice Arzneimittel Putter, Lannett
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
  • Chapter 2: Quantitative analysis of Attention Deficit Hyperactivity Disorder (ADHD) market size and growth potential at global, regional, and country levels.
  • Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
  • Chapter 4: Type-based segmentation analysis – Uncovering blue ocean markets (e.g., Non-stimulant in China).
  • Chapter 5: Application-based segmentation analysis – High-growth downstream opportunities (e.g., Retail Pharmacy in India).
  • Chapter 6: Regional revenue breakdown by company, type, application and customer.
  • Chapter 7: Key manufacturer profiles – Financials, product portfolios, and strategic developments.
  • Chapter 8: Market dynamics – Drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 9: Actionable conclusions and strategic recommendations.
  • Why This Report?
  • Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Attention Deficit Hyperactivity Disorder (ADHD) value chain, addressing:

FAQ for this report

What is the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market size in 2031?

Ans: The Attention Deficit Hyperactivity Disorder (ADHD) Sales Market size in 2031 will be US$ 18550 million.

Who are the main players in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market report?

Ans: The main players in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market are Takeda, Johnson & Johnson, Novartis, Eli Lilly, Tris Pharma, Neos Therapeutics, Mallinckrodt, Amneal Pharmaceuticals, Noven Pharmaceuticals, Purdue Parma, Zhengdafenhai, Highland Therapeutics, Jubilant Life Sciences, Medice Arzneimittel Putter, Lannett

What are the Application segmentation covered in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market report?

Ans: The Applications covered in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market report are Hospital Pharmacy, Retail Pharmacy

What are the Type segmentation covered in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market report?

Ans: The Types covered in the Attention Deficit Hyperactivity Disorder (ADHD) Sales Market report are Stimulant, Non-stimulant

1 Report Overview
1.1 Study Scope
1.2 Market by Type
1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Distribution Channel
1.3.1 Global Market Share by Distribution Channel: 2020 VS 2024 VS 2031
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Perspective (2020-2031)
2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
2.3 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Region (2020-2025)
2.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Forecast by Region (2026-2031)
2.5 Major Region and Emerging Market Analysis
2.5.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size and Prospective (2020-2031)
2.5.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size and Prospective (2020-2031)
2.5.3 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size and Prospective (2020-2031)
2.5.4 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size and Prospective (2020-2031)
3 Breakdown Data by Type
3.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Historic Market Size by Type (2020-2025)
3.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Forecasted Market Size by Type (2026-2031)
3.3 Different Types Attention Deficit Hyperactivity Disorder (ADHD) Representative Players
4 Breakdown Data by Distribution Channel
4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Historic Market Size by Distribution Channel (2020-2025)
4.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Forecasted Market Size by Distribution Channel (2026-2031)
4.3 New Sources of Growth in Attention Deficit Hyperactivity Disorder (ADHD) Application
5 Competition Landscape by Players
5.1 Global Top Players by Revenue
5.1.1 Global Top Attention Deficit Hyperactivity Disorder (ADHD) Players by Revenue (2020-2025)
5.1.2 Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Players (2020-2025)
5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
5.3 Players Covered: Ranking by Attention Deficit Hyperactivity Disorder (ADHD) Revenue
5.4 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Concentration Analysis
5.4.1 Global Attention Deficit Hyperactivity Disorder (ADHD) Market Concentration Ratio (CR5 and HHI)
5.4.2 Global Top 10 and Top 5 Companies by Attention Deficit Hyperactivity Disorder (ADHD) Revenue in 2024
5.5 Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD) Head office and Area Served
5.6 Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD), Product and Application
5.7 Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD), Date of Enter into This Industry
5.8 Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America Market: Players, Segments and Downstream
6.1.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
6.1.2 North America Market Size by Type
6.1.2.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025)
6.1.2.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
6.1.3 North America Market Size by Distribution Channel
6.1.3.1 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025)
6.1.3.2 North America Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
6.1.4 North America Market Trend and Opportunities
6.2 Europe Market: Players, Segments and Downstream
6.2.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
6.2.2 Europe Market Size by Type
6.2.2.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025)
6.2.2.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
6.2.3 Europe Market Size by Distribution Channel
6.2.3.1 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025)
6.2.3.2 Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
6.2.4 Europe Market Trend and Opportunities
6.3 Asia-Pacific Market: Players, Segments and Downstream
6.3.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
6.3.2 Asia-Pacific Market Size by Type
6.3.2.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025)
6.3.2.2 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
6.3.3 Asia-Pacific Market Size by Distribution Channel
6.3.3.1 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025)
6.3.3.2 Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
6.3.4 Asia-Pacific Market Trend and Opportunities
6.4 Japan Market: Players, Segments and Downstream
6.4.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025)
6.4.2 Japan Market Size by Type
6.4.2.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025)
6.4.2.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
6.4.3 Japan Market Size by Distribution Channel
6.4.3.1 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025)
6.4.3.2 Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
6.4.4 Japan Market Trend and Opportunities
7 Key Players Profiles
7.1 Takeda
7.1.1 Takeda Company Details
7.1.2 Takeda Business Overview
7.1.3 Takeda Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.1.4 Takeda Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.1.5 Takeda Recent Development
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Details
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.2.4 Johnson & Johnson Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.2.5 Johnson & Johnson Recent Development
7.3 Novartis
7.3.1 Novartis Company Details
7.3.2 Novartis Business Overview
7.3.3 Novartis Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.3.4 Novartis Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.3.5 Novartis Recent Development
7.4 Eli Lilly
7.4.1 Eli Lilly Company Details
7.4.2 Eli Lilly Business Overview
7.4.3 Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.4.4 Eli Lilly Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.4.5 Eli Lilly Recent Development
7.5 Tris Pharma
7.5.1 Tris Pharma Company Details
7.5.2 Tris Pharma Business Overview
7.5.3 Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.5.4 Tris Pharma Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.5.5 Tris Pharma Recent Development
7.6 Neos Therapeutics
7.6.1 Neos Therapeutics Company Details
7.6.2 Neos Therapeutics Business Overview
7.6.3 Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.6.4 Neos Therapeutics Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.6.5 Neos Therapeutics Recent Development
7.7 Mallinckrodt
7.7.1 Mallinckrodt Company Details
7.7.2 Mallinckrodt Business Overview
7.7.3 Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.7.4 Mallinckrodt Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.7.5 Mallinckrodt Recent Development
7.8 Amneal Pharmaceuticals
7.8.1 Amneal Pharmaceuticals Company Details
7.8.2 Amneal Pharmaceuticals Business Overview
7.8.3 Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.8.4 Amneal Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.8.5 Amneal Pharmaceuticals Recent Development
7.9 Noven Pharmaceuticals
7.9.1 Noven Pharmaceuticals Company Details
7.9.2 Noven Pharmaceuticals Business Overview
7.9.3 Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.9.4 Noven Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.9.5 Noven Pharmaceuticals Recent Development
7.10 Purdue Parma
7.10.1 Purdue Parma Company Details
7.10.2 Purdue Parma Business Overview
7.10.3 Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.10.4 Purdue Parma Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.10.5 Purdue Parma Recent Development
7.11 Zhengdafenhai
7.11.1 Zhengdafenhai Company Details
7.11.2 Zhengdafenhai Business Overview
7.11.3 Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.11.4 Zhengdafenhai Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.11.5 Zhengdafenhai Recent Development
7.12 Highland Therapeutics
7.12.1 Highland Therapeutics Company Details
7.12.2 Highland Therapeutics Business Overview
7.12.3 Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.12.4 Highland Therapeutics Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.12.5 Highland Therapeutics Recent Development
7.13 Jubilant Life Sciences
7.13.1 Jubilant Life Sciences Company Details
7.13.2 Jubilant Life Sciences Business Overview
7.13.3 Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.13.4 Jubilant Life Sciences Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.13.5 Jubilant Life Sciences Recent Development
7.14 Medice Arzneimittel Putter
7.14.1 Medice Arzneimittel Putter Company Details
7.14.2 Medice Arzneimittel Putter Business Overview
7.14.3 Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.14.4 Medice Arzneimittel Putter Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.14.5 Medice Arzneimittel Putter Recent Development
7.15 Lannett
7.15.1 Lannett Company Details
7.15.2 Lannett Business Overview
7.15.3 Lannett Attention Deficit Hyperactivity Disorder (ADHD) Introduction
7.15.4 Lannett Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
7.15.5 Lannett Recent Development
8 Attention Deficit Hyperactivity Disorder (ADHD) Market Dynamics
8.1 Attention Deficit Hyperactivity Disorder (ADHD) Industry Trends
8.2 Attention Deficit Hyperactivity Disorder (ADHD) Market Drivers
8.3 Attention Deficit Hyperactivity Disorder (ADHD) Market Challenges
8.4 Attention Deficit Hyperactivity Disorder (ADHD) Market Restraints
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma
NEOS Therapeutics
Mallinckrodt plc
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengdafenhai
Highland Therapeutics
Jubilant Life Sciences
Medice Arzneimittel Putter
Lannett
List of Tables
 Table 1. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size Growth by Distribution Channel (US$ Million): 2020 VS 2024 VS 2031
 Table 3. Global Market Attention Deficit Hyperactivity Disorder (ADHD) Market Size (US$ Million) by Region:2020 VS 2024 VS 2031
 Table 4. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Market Share by Region (2020-2025)
 Table 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Share by Region (2020-2025)
 Table 6. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Forecast by Region (2026-2031)
 Table 7. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Share Forecast by Region (2026-2031)
 Table 8. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025) & (US$ Million)
 Table 9. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Type (2020-2025)
 Table 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 11. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Type (2026-2031)
 Table 12. Representative Players of Each Type
 Table 13. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025) & (US$ Million)
 Table 14. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Distribution Channel (2020-2025)
 Table 15. Global Attention Deficit Hyperactivity Disorder (ADHD) Forecasted Market Size by Distribution Channel (2026-2031) & (US$ Million)
 Table 16. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Distribution Channel (2026-2031)
 Table 17. New Sources of Growth in Attention Deficit Hyperactivity Disorder (ADHD) Application
 Table 18. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Players (2020-2025) & (US$ Million)
 Table 19. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Players (2020-2025)
 Table 20. Global Top Attention Deficit Hyperactivity Disorder (ADHD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention Deficit Hyperactivity Disorder (ADHD) as of 2024)
 Table 21. Ranking of Global Top Attention Deficit Hyperactivity Disorder (ADHD) Companies by Revenue (US$ Million) in 2024
 Table 22. Global 5 Largest Players Market Share by Attention Deficit Hyperactivity Disorder (ADHD) Revenue (CR5 and HHI) & (2020-2025)
 Table 23. Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD), Headquarters and Area Served
 Table 24. Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD), Product and Application
 Table 25. Global Key Players of Attention Deficit Hyperactivity Disorder (ADHD), Date of Enter into This Industry
 Table 26. Mergers & Acquisitions, Expansion Plans
 Table 27. North America Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025) & (US$ Million)
 Table 28. North America Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Company (2020-2025)
 Table 29. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025) & (US$ Million)
 Table 30. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025) & (US$ Million)
 Table 31. Europe Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025) & (US$ Million)
 Table 32. Europe Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Company (2020-2025)
 Table 33. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025) & (US$ Million)
 Table 34. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025) & (US$ Million)
 Table 35. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025) & (US$ Million)
 Table 36. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Company (2020-2025)
 Table 37. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025) & (US$ Million)
 Table 38. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025) & (US$ Million)
 Table 39. Japan Attention Deficit Hyperactivity Disorder (ADHD) Revenue by Company (2020-2025) & (US$ Million)
 Table 40. Japan Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Company (2020-2025)
 Table 41. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Type (2020-2025) & (US$ Million)
 Table 42. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Size by Distribution Channel (2020-2025) & (US$ Million)
 Table 43. Takeda Company Details
 Table 44. Takeda Business Overview
 Table 45. Takeda Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 46. Takeda Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 47. Takeda Recent Development
 Table 48. Johnson & Johnson Company Details
 Table 49. Johnson & Johnson Business Overview
 Table 50. Johnson & Johnson Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 51. Johnson & Johnson Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 52. Johnson & Johnson Recent Development
 Table 53. Novartis Company Details
 Table 54. Novartis Business Overview
 Table 55. Novartis Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 56. Novartis Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 57. Novartis Recent Development
 Table 58. Eli Lilly Company Details
 Table 59. Eli Lilly Business Overview
 Table 60. Eli Lilly Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 61. Eli Lilly Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 62. Eli Lilly Recent Development
 Table 63. Tris Pharma Company Details
 Table 64. Tris Pharma Business Overview
 Table 65. Tris Pharma Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 66. Tris Pharma Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 67. Tris Pharma Recent Development
 Table 68. Neos Therapeutics Company Details
 Table 69. Neos Therapeutics Business Overview
 Table 70. Neos Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 71. Neos Therapeutics Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 72. Neos Therapeutics Recent Development
 Table 73. Mallinckrodt Company Details
 Table 74. Mallinckrodt Business Overview
 Table 75. Mallinckrodt Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 76. Mallinckrodt Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 77. Mallinckrodt Recent Development
 Table 78. Amneal Pharmaceuticals Company Details
 Table 79. Amneal Pharmaceuticals Business Overview
 Table 80. Amneal Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 81. Amneal Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 82. Amneal Pharmaceuticals Recent Development
 Table 83. Noven Pharmaceuticals Company Details
 Table 84. Noven Pharmaceuticals Business Overview
 Table 85. Noven Pharmaceuticals Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 86. Noven Pharmaceuticals Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 87. Noven Pharmaceuticals Recent Development
 Table 88. Purdue Parma Company Details
 Table 89. Purdue Parma Business Overview
 Table 90. Purdue Parma Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 91. Purdue Parma Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 92. Purdue Parma Recent Development
 Table 93. Zhengdafenhai Company Details
 Table 94. Zhengdafenhai Business Overview
 Table 95. Zhengdafenhai Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 96. Zhengdafenhai Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 97. Zhengdafenhai Recent Development
 Table 98. Highland Therapeutics Company Details
 Table 99. Highland Therapeutics Business Overview
 Table 100. Highland Therapeutics Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 101. Highland Therapeutics Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 102. Highland Therapeutics Recent Development
 Table 103. Jubilant Life Sciences Company Details
 Table 104. Jubilant Life Sciences Business Overview
 Table 105. Jubilant Life Sciences Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 106. Jubilant Life Sciences Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 107. Jubilant Life Sciences Recent Development
 Table 108. Medice Arzneimittel Putter Company Details
 Table 109. Medice Arzneimittel Putter Business Overview
 Table 110. Medice Arzneimittel Putter Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 111. Medice Arzneimittel Putter Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 112. Medice Arzneimittel Putter Recent Development
 Table 113. Lannett Company Details
 Table 114. Lannett Business Overview
 Table 115. Lannett Attention Deficit Hyperactivity Disorder (ADHD) Product
 Table 116. Lannett Revenue in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025) & (US$ Million)
 Table 117. Lannett Recent Development
 Table 118. Attention Deficit Hyperactivity Disorder (ADHD) Market Trends
 Table 119. Attention Deficit Hyperactivity Disorder (ADHD) Market Drivers
 Table 120. Attention Deficit Hyperactivity Disorder (ADHD) Market Challenges
 Table 121. Attention Deficit Hyperactivity Disorder (ADHD) Market Restraints
 Table 122. Research Programs/Design for This Report
 Table 123. Key Data Information from Secondary Sources
 Table 124. Key Data Information from Primary Sources


List of Figures
 Figure 1. Attention Deficit Hyperactivity Disorder (ADHD) Product Picture
 Figure 2. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type: 2024 VS 2031
 Figure 3. Stimulant Features
 Figure 4. Non-stimulant Features
 Figure 5. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel: 2024 VS 2031
 Figure 6. Hospital Pharmacy
 Figure 7. Retail Pharmacy
 Figure 8. Attention Deficit Hyperactivity Disorder (ADHD) Report Years Considered
 Figure 9. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 10. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Attention Deficit Hyperactivity Disorder (ADHD) Revenue Market Share by Region: 2020 VS 2024
 Figure 12. North America Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Growth Rate (2020-2031)
 Figure 13. Europe Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Growth Rate (2020-2031)
 Figure 14. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Growth Rate (2020-2031)
 Figure 15. Japan Attention Deficit Hyperactivity Disorder (ADHD) Revenue (US$ Million) Growth Rate (2020-2031)
 Figure 16. Global Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Players in 2024
 Figure 17. Global Top Attention Deficit Hyperactivity Disorder (ADHD) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attention Deficit Hyperactivity Disorder (ADHD) as of 2024)
 Figure 18. The Top 10 and 5 Players Market Share by Attention Deficit Hyperactivity Disorder (ADHD) Revenue in 2024
 Figure 19. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
 Figure 20. North America Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
 Figure 21. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
 Figure 22. Europe Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
 Figure 23. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
 Figure 24. Asia-Pacific Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
 Figure 25. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Type (2020-2025)
 Figure 26. Japan Attention Deficit Hyperactivity Disorder (ADHD) Market Share by Distribution Channel (2020-2025)
 Figure 27. Takeda Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 28. Johnson & Johnson Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 29. Novartis Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 30. Eli Lilly Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 31. Tris Pharma Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 32. Neos Therapeutics Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 33. Mallinckrodt Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 34. Amneal Pharmaceuticals Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 35. Noven Pharmaceuticals Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 36. Purdue Parma Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 37. Zhengdafenhai Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 38. Highland Therapeutics Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 39. Jubilant Life Sciences Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 40. Medice Arzneimittel Putter Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 41. Lannett Revenue Growth Rate in Attention Deficit Hyperactivity Disorder (ADHD) Business (2020-2025)
 Figure 42. Bottom-up and Top-down Approaches for This Report
 Figure 43. Data Triangulation
 Figure 44. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4250

This license allows only one user to access the PDF.
Electronic (PDF)

$6375

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$8500

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Attention Deficit Hyperactivity Syndrome Treatment Market Research Report 2025
Attention Deficit Hyperactivity Disorder Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Attention deficit Hyperactivity Disorder ADHD Therapeutics Market Research Report 2024
ADHD Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Children Attention Deficit and Hyperactivity Disorder Market Research Report 2025
Global Attention Deficit and Hyperactivity Disorder Market Research Report 2025
Global Children ADHD Treatment Market Research Report 2024
Global Adult Attention Deficit and Hyperactivity Disorder Market Research Report 2025
Attention Deficit Hyperactivity Disorder ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
ADHD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global ADHD Drug Treatment Market Research Report 2024
Global Attention Deficit Hyperactivity Disorder Treatment Market Research Report 2024
Global ADHD Medications Market Insights Forecast to 2030
Global Attention Deficit Hyperactivity Disorder ADHD Medications Market Research Report 2024
Global ADHD Medication Market Research Report 2025
Global Pediatric ADHD Drugs Market Research Report 2025
Global ADHD Management Software Market Research Report 2024
Global Adult ADHD Treatment Market Research Report 2024
Global ADHD Apps Market Research Report 2024
Global Anti Adhd Supplements Market Research Report 2024

RELATED REPORTS

Global Attention Deficit Hyperactivity Disorder (ADHD) Drugs Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-13Z8760
Tue Sep 09 00:00:00 UTC 2025

Add to Cart

Global Intracranial Pressure (ICP) Monitoring Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-37L4006
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Brain Disease Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-12P6151
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-3X6389
Mon Sep 08 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions